Related references
Note: Only part of the references are listed.Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
Jaafar Bennouna et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
V gamma 9V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - Rituximab and trastuzumab
Hirotake Tokuyama et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
PKC zeta-mTOR pathway: a new target for rituximab therapy in follicular lymphoma
Ludivine Leseux et al.
BLOOD (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Recent progress in the management of chronic lymphocytic leukemia
Tadeusz Robak
CANCER TREATMENT REVIEWS (2007)
Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer
Francesco Dieli et al.
CANCER RESEARCH (2007)
Granzyme B induction signalling pathway in acute myeloid leukemia cell lines stimulated by Tumor Necrosis Factor alpha and Fas Ligand
Fabien Guilloton et al.
CELLULAR SIGNALLING (2007)
Human γδ T lymphocytes strip and kill tumor cells simultaneously
Julie Gertner et al.
IMMUNOLOGY LETTERS (2007)
Immune surveillance of tumors
Jeremy B. Swann et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Prospects for the use of NK cells in immunotherapy of human cancer
Hans-Gustaf Ljunggren et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Rituximab therapy in malignant lymphoma
B. Coiffier
ONCOGENE (2007)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Neil E. Kay et al.
BLOOD (2007)
Perspectives of gamma delta T cells in tumor immunology
Dieter Kabelitz et al.
CANCER RESEARCH (2007)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model
H Sicard et al.
JOURNAL OF IMMUNOLOGY (2005)
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
M Beyer et al.
BLOOD (2005)
Drug-induced expansion and differentiation of Vγ9Vδ2 T cells in vivo:: The role of exogenous IL-2
R Casetti et al.
JOURNAL OF IMMUNOLOGY (2005)
Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites
M Bonneville et al.
MICROBES AND INFECTION (2005)
Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma
E Viey et al.
JOURNAL OF IMMUNOLOGY (2005)
Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human γδ T cells to anaplastic large cell lymphoma
M Poupot et al.
JOURNAL OF IMMUNOLOGY (2005)
Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro
K Thompson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
FcγRIII discriminates between 2 subsets of Vγ9Vδ2 effector cells with different responses and activation pathways
DF Angelini et al.
BLOOD (2004)
Characterization of tumor reactivity of human Vγ9Vδ2 yδ T cells in vitro and in SCID mice in vivo
D Kabelitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Natural killer cell signaling pathways
E Vivier et al.
SCIENCE (2004)
From the bench to the bedside: ways to improve rituximab efficacy
G Cartron et al.
BLOOD (2004)
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
MS Cragg et al.
BLOOD (2004)
Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys
C Schröder et al.
TRANSPLANT IMMUNOLOGY (2003)
Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo
F Dieli et al.
BLOOD (2003)
Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites
F Dieli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Rituximab in B-cell chronic lymphocytic leukemia
TS Lin et al.
SEMINARS IN ONCOLOGY (2003)
γδ T cells for immune therapy of patients with lymphoid malignancies
M Wilhelm et al.
BLOOD (2003)
Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells
HJ Gober et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Synaptic transfer by human γδ T cells stimulated with soluble or cellular antigens
E Espinosa et al.
JOURNAL OF IMMUNOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Production of TNF-α by human Vγ9Vδ2 T cells via engagement of FcγRIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen
V Lafont et al.
JOURNAL OF IMMUNOLOGY (2001)
Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells
E Espinosa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Gamma/delta T cells provide innate immunity against renal cell carcinoma
H Kobayashi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2001)
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome
L Fayad et al.
BLOOD (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
